CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares of the company's stock, valued at approximately $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
CytomX Therapeutics Trading Down 0.6 %
NASDAQ CTMX opened at $0.67 on Friday. The business's 50-day moving average price is $0.77 and its 200 day moving average price is $0.99. CytomX Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $5.85. The company has a market capitalization of $53.34 million, a PE ratio of 3.92 and a beta of 1.05.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.45. The business had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Equities analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.
Institutional Investors Weigh In On CytomX Therapeutics
A number of institutional investors have recently made changes to their positions in CTMX. Miller Financial Services LLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter valued at approximately $26,000. Traphagen Investment Advisors LLC acquired a new position in CytomX Therapeutics during the 4th quarter valued at approximately $31,000. Algert Global LLC acquired a new position in CytomX Therapeutics during the 4th quarter valued at approximately $35,000. Velan Capital Investment Management LP acquired a new position in CytomX Therapeutics during the 4th quarter valued at approximately $36,000. Finally, Aspire Growth Partners LLC acquired a new position in CytomX Therapeutics during the 4th quarter valued at approximately $42,000. 67.77% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
CTMX has been the topic of several recent analyst reports. StockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Monday, March 10th. HC Wainwright reiterated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $5.00 target price on shares of CytomX Therapeutics in a research note on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.02.
Check Out Our Latest Analysis on CytomX Therapeutics
CytomX Therapeutics Company Profile
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
